All News

Jeff A. Goad, PharmD, MPH, discusses the latest RSV vaccination guidelines and recommendations for 2025, highlighting vaccine options, target populations, timing considerations, evolving CDC policies, and the role of pharmacists in immunization efforts.

In a debate at the 2025 APhA Annual Meeting, speakers highlighted GLP-1s’ advantages in stroke prevention and weight loss vs SGLT2s’ superiority in heart failure, CV death reduction, and renal protection.

Pharmacists are pivotal in expanding reproductive health care access through patient education and collaboration.

Pharmacists are leading the way in personalized medicine through strategic pharmacogenetic implementation.

Pharmacists can empower patient RSV vaccination through strategic communication and personalized care.

Two pharmacists at the 2025 APhA Annual Meeting debate the role of continuous glucose monitoring (CGM) for non-insulin users, highlighting evolving guidelines, emerging clinical evidence, cost and coverage challenges, and the need for further research to justify widespread adoption.

Pharmacists can navigate career paths through passion, adaptability, and patient-centered soft skills.

AI is offering new ways to support pharmacists' decision-making and patient care.

Contraceptive options have expanded since 1960, with pharmacists today playing a growing role as prescribers of contraception and studies showing the benefit of pharmacist-driven contraception clinics.

Sally Arif, PharmD, BCCP, discusses her presentation on the critical role of pharmacists in addressing health disparities by improving communication, fostering cultural competence, and promoting pharmacoequity.

The study aims to address lingering public concerns, but its findings and communication have the potential to impact vaccine confidence and public health efforts.

Nakia Eldridge, PharmD, MBA, shares insights for health system and community pharmacists attending the 2025 APhA Annual Meeting & Exposition.

Patients with central nervous system (CNS) involvement achieved favorable outcomes with chimeric antigen receptor (CAR) T-cell therapy.

Non-high-density lipoprotein cholesterol was found to be more effective at predicting cardiovascular events such as stroke, myocardial outcomes, heart failure, and others compared with low-density lipoprotein cholesterol.

Sjögren's disease is one of the most common chronic autoimmune diseases that affects 4 million individuals around the world.

Allison Ju-Chen Hu, PhD and Yuhua Bao, PhD describe results of their landmark study that found significant differences in opioid prescriptions in racially and ethnically minoritized communities.

This subset of heart failure requires unique therapeutic considerations.

After decades without improvements, an expert with Baptist Health described the small cell lung cancer (SCLC) space as “exciting” following multiple innovations in the past few years.

The new indication for guselkumab in Crohn disease builds off a previous approval in ulcerative colitis, providing patients a treatment option for the major forms of inflammatory bowel disease.

Vutrisiran becomes the first and only therapeutic FDA-approved to treat cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults.

As cases rise, experts warn that vitamin A supplementation should not be used as a replacement for vaccination.

The agent is the only approved therapy designed to address the underlying mechanisms of the disease.

The FDA reviews NDAs and BLAs to approve medications for sale and marketing in the US with decisions required by the PDUFA date.

The launch of ustekinumab-stba following its FDA approval expands patient access to this therapy with a variety of indications.

Health care professionals in the study found it challenging to manage the complexities of disordered eating in patients with type 1 diabetes alongside their other responsibilities.

An expert roundtable discussed what consumers and pharmacists should be aware of as compounded versions of glucagon-like peptide-1 receptor agonists continue to proliferate.

Allogeneic stem cell transplant (allo-SCT) conditioning with busulfan/fludarabine with thiotepa and posttransplant cyclophosphamide induced improved 2-year progression-free survival and overall survival in patients with myelofibrosis, especially older adults.